Stock Events

Stock Events

Swedish Orphan Biovitrum AB 

$24.44
16
-$0.17-0.69% 14:10 Today

Statistics

Day High
26
Day Low
26
52W High
29.32
52W Low
13.57
Volume
150
Avg. Volume
141
Mkt Cap
8.74B
P/E Ratio
178.57
Dividend Yield
-
Dividend
-

Upcoming

Earnings

27OctExpected
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Next
-0.88
-0.37
0.13
0.64
Expected EPS
0.6415466318
Actual EPS
N/A

Financials

1.47%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
3BRevenue
44.12MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow SWOBY. It's not an investment recommendation.
Palo Alto Networks
3
PANW
Telefonaktiebolaget L M Ericsson
3
ERIC-B.ST
Skandinaviska Enskilda Banken AB.
3
SEB-A.ST
Lundin Mining
3
LUMI.ST

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap138.91B
Vertex Pharmaceuticals is a competitor because it also focuses on rare diseases, similar to Swedish Orphan Biovitrum, with a strong emphasis on cystic fibrosis treatments.
Biogen
BIIB
Mkt Cap32.03B
Biogen competes in the rare disease space, particularly in areas like spinal muscular atrophy and multiple sclerosis, overlapping with some of Swedish Orphan Biovitrum's therapeutic areas.
Gilead Sciences
GILD
Mkt Cap181.18B
Gilead Sciences competes with Swedish Orphan Biovitrum through its focus on antiviral drugs for HIV, hepatitis B, and hepatitis C, as well as its expansion into other areas of high unmet medical need.
AMGEN
AMGN
Mkt Cap237.52B
Amgen competes in the biopharmaceutical field, focusing on treatments for serious illnesses, including areas that overlap with Swedish Orphan Biovitrum's focus on rare diseases.
Regeneron Pharmaceuticals
REGN
Mkt Cap85.87B
Regeneron Pharmaceuticals is a competitor due to its focus on developing and commercializing treatments for eye diseases, rare diseases, and cancer, areas that Swedish Orphan Biovitrum also targets.
Novo Nordisk
NVO
Mkt Cap206.69B
Novo Nordisk is a leading company in diabetes care but also competes in the biopharmaceutical space, including treatments for rare blood disorders, overlapping with Swedish Orphan Biovitrum's market.
Pfizer
PFE
Mkt Cap159.99B
Pfizer is a broad-based competitor, with a significant presence in rare diseases through its Rare Disease unit, making it a competitor across several of Swedish Orphan Biovitrum's therapeutic areas.
Astrazeneca
AZN
Mkt Cap257.42B
AstraZeneca, especially after its acquisition of Alexion Pharmaceuticals, competes in the rare disease market, directly challenging Swedish Orphan Biovitrum's portfolio of rare disease therapies.

About

SWEDISH ORPHAN BIOVIT ORD
Show more...
CEO
Guido Oelkers
Employees
1888
Country
Sweden
ISIN
US8703212055
WKN
000A3D8W3

Listings

MI
IT
1SOBI.MI
STU
DE
B6E.STU
LSE
GB
0MTD.LSE
MU
DE
B6E.MU

0 Comments

Share your thoughts

FAQ

What is Swedish Orphan Biovitrum AB stock price today?▼
The current price of SWOBY is $24.44 USD — it has decreased by -0.69% in the past 24 hours. Watch Swedish Orphan Biovitrum AB stock price performance more closely on the chart.
What is Swedish Orphan Biovitrum AB stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Swedish Orphan Biovitrum AB stocks are traded under the ticker SWOBY.
Is Swedish Orphan Biovitrum AB stock price growing?▼
SWOBY stock has risen by +0.53% compared to the previous week, the month change is a +4% rise, over the last year Swedish Orphan Biovitrum AB has showed a +55.17% increase.
What is Swedish Orphan Biovitrum AB market cap?▼
Today Swedish Orphan Biovitrum AB has the market capitalization of 8.74B
When is the next Swedish Orphan Biovitrum AB earnings date?▼
Swedish Orphan Biovitrum AB is going to release the next earnings report on October 27, 2026.
What were Swedish Orphan Biovitrum AB earnings last quarter?▼
SWOBY earnings for the last quarter are 0.32 USD per share, whereas the estimation was 0.35 USD resulting in a -7.52% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Swedish Orphan Biovitrum AB revenue for the last year?▼
Swedish Orphan Biovitrum AB revenue for the last year amounts to 3B USD.
What is Swedish Orphan Biovitrum AB net income for the last year?▼
SWOBY net income for the last year is 44.12M USD.
How many employees does Swedish Orphan Biovitrum AB have?▼
As of August 28, 2026, the company has 1,888 employees.
In which sector is Swedish Orphan Biovitrum AB located?▼
Swedish Orphan Biovitrum AB operates in the Health & Wellness sector.
When did Swedish Orphan Biovitrum AB complete a stock split?▼
Swedish Orphan Biovitrum AB has not had any recent stock splits.
Where is Swedish Orphan Biovitrum AB headquartered?▼
Swedish Orphan Biovitrum AB is headquartered in Stockholm, Sweden.